|
|||||
|
|
||||||
Originally published as JCO Early Release 10.1200/JCO.2005.03.0999 on December 5 2005 © 2006 American Society of Clinical Oncology. Prognostic Significance of Chromosome Aberrations in High-Grade Soft Tissue SarcomasFrom the Departments of Clinical Genetics, Occupational and Environmental Medicine, and Orthopedics, Lund University Hospital, Lund; and the Department of Orthopedics, Karolinska Hospital, Stockholm, Sweden Address reprint requests to Fredrik Mertens, MD, PhD, Department of Clinical Genetics, Lund University Hospital, SE-221 85 Lund, Sweden; e-mail: fredrik.mertens{at}med.lu.se PURPOSE: To investigate whether previously observed correlations between tumor karyotype and risk of metastases could be reproduced in an independent set of high-grade soft tissue sarcomas (STSs). PATIENTS AND METHODS: In a previous study on high-grade STSs with clonal chromosome aberrations, we identified a number of cytogenetic variables, besides tumor grade and size, that were associated with significantly increased risk of metastases. In the present study, we have tested the predictive value of these cytogenetic variables in a new set of 156 high-grade STSs, all located in the extremities or trunk wall.
RESULTS: Of the 10 cytogenetic variables that turned out to provide prognostic information in the previous series, encompassing 122 trunk wall or extremity STSs, three were significantly associated with metastases also in the new series. In a final Cox regression analysis including these three cytogenetic variables, as well as tumor grade and size, on the combined series of 278 high-grade STSs, four parameters were found to be significantly associated with metastasis risk: tumor grade 3, tumor size CONCLUSION: Our findings suggest that independent prognostic information may be gained from cytogenetic analysis of high-grade STS. Supported by the Swedish Cancer Society and the Swedish Children's Cancer Fund. Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org. Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
|
|
|||||||||||
|
Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|